UCB (OTCMKTS:UCBJF) Shares Gap Down – Should You Sell?

UCB SA (OTCMKTS:UCBJF)’s stock price gapped down before the market opened on Wednesday. The stock had previously closed at $328.91, but opened at $314.48. UCB shares last traded at $314.48, with a volume of 27 shares changing hands.

Analyst Ratings Changes

Several brokerages have recently issued reports on UCBJF. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Finally, Stephens restated an “overweight” rating on shares of UCB in a report on Wednesday, October 21st. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, UCB has a consensus rating of “Moderate Buy”.

UCB Trading Down 4.4%

The business has a 50-day moving average price of $262.64 and a 200-day moving average price of $286.33. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB is a Belgian biopharmaceutical company founded in 1928 and headquartered in Brussels. It discovers, develops and commercializes medicines, with a focus on neurological and immunological conditions. Its products include treatments for epilepsy, such as Keppra, Briviact and Nayzilam, as well as medicines for inflammatory diseases, including Cimzia and Bimzelx. UCB also develops therapies for other serious conditions, including myasthenia gravis. The company serves patients and healthcare providers in markets around the world.